Patient info Open main menu

Vascalpha 10 mg prolonged-release tablets (Felodipine) – patient leaflet, side effects, dosage

Medicine status: Prescription only (POM) Details

Medicine strength:
10 mg
Contains active substance:
ATC code:
Similar medicines:

Sources: Original (products.mhra.gov.uk)

Patient leaflet - Vascalpha 10 mg prolonged-release tablets (Felodipine)

»B|qei.


6w OT


asedpH peteuofMd'Bui OT eqditnsta:...



Vas calpha i ffJ Prolonged Release Tablets Felodipine

28 Tablets


46×18×115

V1–190828B


1 prolonged release tablet contains lOmg of Felodipine. Also includes: lactose monohydrate (see leaflet for further information). For oral use. Swallow the tablets whole. Use as directed by physician. Keep out of the sight and reach of children. Do not store the tablets above 25°C.


10 mg



Vascalpha 10 mg Prolonged Release Tablets Felodipine

28 Tablets




Dispensing Label Place Here



8mm → pharmacode

height

25mm maximum pharmacode length


Q LU £


accord

Vascalphaf10 mg

Prolonged Release Tablets

(Felodipine)

Q LU £

accord

Vascalpha[10 mg

Prolonged Release Tablets

(Felodipine)

116mm

Sources: Original (products.mhra.gov.uk)

Facts about Vascalpha 10 mg prolonged-release tablets (Felodipine)

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Felodipine
Strength 10 mg
Pharmaceutical form Modified-release tablet
Reddish brown, round, biconvex, film coated prolonged release tablets with imprint 10
How is it taken Oral
Excipients Lactose monohydrate, Microcrystalline cellulose, Hypromellose, Povidone K25, Propyl gallate (Ph.Eur.), Colloidal anhydrous silica, Magnesium stearate (Ph.Eur.), Iron oxide red (E172), Iron oxide yellow (E172), Titanium dioxide (E171), Talcum, Propylene glycol
Pack sizes 28 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 4 years.
Storage Do not store above 25°C.
Drug group (ATC)
  1. C Cardiovascular system drugs
    1. C08 Calcium channel blockers
      1. C08C Selective calcium channel blockers with mainly vascular effects
        1. C08CA Dihydropyridine derivative selective calcium channel blockers with mainly vascular effects
          1. C08CA02 felodipine
Marketing authorisation PL 00142/0542 (first authorised 17 September 2006)
Marketing authorisation holder Accord-UK Ltd
Codes GTIN 5012617013392 · BNF 02060200

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.